Published in final edited form as:

Mol Cancer Ther. 2018 March ; 17(3): 671–676. doi:10.1158/1535-7163.MCT-17-0673.

Phase 1 dose-escalation study of anti CTLA-4 antibody ipilimumab and lenalidomide in patients with advanced cancers

Divya Sakamuri¹, Isabella C. Glitza², Sonia L. Betancourt Cuellar³, Vivek Subbiah¹, Siqing Fu¹, Apostolia M. Tsimberidou¹, Jennifer J. Wheler¹, David S. Hong¹, Aung Naing¹, Gerald S. Falchook^{1,6}, Michelle A. Fanale⁴, Maria E. Cabanillas⁵, and Filip Janku¹

¹Department of Investigational Cancer Therapeutics (Phase 1 Clinical Trials Program), The University of Texas MD Anderson Cancer Center; Houston, TX, USA

²Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center; Houston, TX, USA

³Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center; Houston, TX, USA

⁴Department of Lymphoma and Myeloma Oncology, The University of Texas MD Anderson Cancer Center; Houston, TX, USA

⁵Department of Endocrine Neoplasia and Hormonal Disorders; The University of Texas MD Anderson Cancer Center; Houston, TX, USA

⁶Sarah Cannon Research Institute at HealthONE; Denver, CO, USA

Abstract

Preclinical data suggest that combining a check point inhibition with immunomodulatory derivative can increase anticancer response. We designed a dose escalation study using a 3+3 design to determine the safety, maximum tolerated dose (MTD) or recommended phase 2 dose (R2PD) and dose limiting toxicities (DLT) of the anti-CTLA-4 antibody ipilimumab (1.5-3mg/kg intravenously every 28 days × 4) and lenalidomide (10-25mg orally daily for 21 of 28 days until disease progression or unacceptable toxicity) in advanced cancers. Total of 36 patients (Hodgkin lymphoma, 7; melanoma, 5; leiomyosarcoma, 4; renal cancer, 3; thyroid cancer, 3; other cancers, 14; median of 3 prior therapies) were enrolled. The MTD has not been reached and ipilimumab 3mg/kg and lenalidomide 25 mg have been declared as R2PD. DLT were grade (G) 3 rash (3 patients) and G3 pancreatitis (1 patient). G3/4 drug related toxicities other than DLT were G3 anemia (5 patients), G3 thromboembolism (2 patients), G3 thrombocytopenia, rash, hypopituitarism, G3 pneumonitis, G3 transaminitis and G4 hypopituitarism (all in 1 patient). Eight patients had tumor shrinkage per immune-related response criteria (−79% to −2%) including a PR (−79% for 7.2+ months) in a refractory Hodgkin lymphoma. Using comprehensive genomic profiling a total mutation burden (mutations/Mb) was evaluated in 17 patients, with one of the patients achieving a PR demonstrated intermediate mutation burden. In conclusion, combination of

ipilimumab and lenalidomide is well tolerated and demonstrated preliminary signals of activity in patients with refractory Hodgkin lymphoma and other advanced cancers.

Keywords

Ipilimumab; Lenalidomide; anti CTLA-4; immunomodulation; phase 1

Introduction

Cytotoxic T-lymphocyte antigen 4 (CTLA-4) functions as an immune checkpoint, negatively regulating the duration and intensity of the immune response.(1) Blocking this checkpoint allows the immune response to persist and increase the immune system's ability to detect and destroy cancer cells. Ipilimumab is a monoclonal antibody that binds to CTLA-4, which activates T-cell driven anticancer immune response by virtue of blocking the interaction between CTLA-4 and its ligands, CD80/CD86. Ipilimumab is approved by the US Food and Drug Administration (FDA) for treatment of metastatic melanoma.(1)

Lenalidomide, a 4-amino-glutamyl analogue derivative of thalidomide, is a so called immunomodulatory derivative (IMiD), which affects both cellular and humoral immunity and also has antiangiogenic and other antitumor properties, is approved by FDA for treatment of multiple myeloma.(2) In multiple myeloma models, immunomodulatory effects of lenalidomide does not only target the multiple myeloma cells directly, but also induces anticancer activity of immune effector cells. However, lenalidomide does not alter myeloid-derived suppressor cell (MDSC)-mediated tumor growth and immune suppression.(3–5) Furthermore, in vitro experiments in multiple myeloma cells demonstrated that immune response from the check point blockade can be enhanced by lenalidomide with decrease in MDSC-mediated cell growth, which provides framework for clinical evaluation of combination therapy.(6) Therefore, we designed a phase I clinical study with ipilimumab and lenalidomide to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D), safety and early signals of clinical activity in patients with advanced cancers.

Materials and Methods

This study was a non-randomized, dose-escalation phase 1 clinical trial of ipilimumab and lenalidomide (NCT01750983) performed at The University of Texas MD Anderson Cancer Center (MD Anderson). The primary objective was to determine the MTD or recommended phase 2 dose (R2PD) and dose-limiting toxicities (DLT) of ipilimumab in combination with lenalidomide in patients with advanced cancer who have progressed on standard therapy. Secondary objectives were to assess preliminary signals of antitumor efficacy. The protocol was approved by the Institutional Review Board (IRB). All patients provided written informed consent prior to enrolling on a study.

We enrolled patients aged 18 years and older with advanced or metastatic malignancy with no available standard therapy referred to the Clinical Center for Targeted Therapy at MD Anderson between May 2013 and April 2016. Patient selection was further narrowed to

those who met all the eligibility criteria. All patients were 3 or more weeks beyond treatment with cytotoxic chemotherapy, therapeutic radiation, and major surgery. Patients who received palliative radiation immediately before or requiring it during treatment were allowed provided that radiation was not delivered to the only site of disease being treated under the protocol. For those who received biologic/targeted therapy as their last treatment, a washout period of 3 weeks or 5 half-lives (whichever was shorter) was required. Other inclusion criteria included an Eastern Cooperative Oncology Group performance status (ECOG) of 0, 1, or 2; adequate organ and bone marrow function, as defined by an absolute neutrophil count of greater or equal to 1,000/ml, a platelet count greater or equal to 50,000/ml, a creatinine clearance of greater or equal to 60ml/min by Cockcroft-Gault calculation, a total bilirubin of less than or equal to 2 times the institutional upper limit of normal, and an alanine aminotransferase level of less than or equal to 5 times the upper limit of normal. Due to the teratogenic nature of lenalidomide, it was required that females use 2 effective contraceptive methods during therapy and at least 4 weeks after completing therapy and for males to use of a latex condom during any sexual contact with females of childbearing potential even if they have undergone a successful vasectomy. In addition, a weekly pregnancy test was performed for the first 8 weeks and at the start of a cycle thereafter in all female patients. Patients were excluded if they had a history of organ transplant, autoimmune disease including inflammatory bowel disease, severe motor or sensory neuropathy, angioedema and those with uncontrolled intercurrent illness, including, but not limited to, uncontrolled infection, uncontrolled asthma, need for hemodialysis or ventilator support.

Patients were enrolled to 5 dose levels using the standard “3+3” dose escalation design (Table1). The starting doses were 1.5mg/kg of ipilimumab and 10mg of lenalidomide and were escalated to 3.0mg/kg of ipilimumab and 25mg of lenalidomide. Ipilimumab was given intravenously on day 1 of a 28 day cycle for 4 doses. Lenalidomide was given orally days 1 through 21 of a 28 day cycle until disease progression. Patients were monitored closely for the first 8 weeks with weekly visits consisting of labs and clinical exam for to assess tolerability. Patients who had DLT or completed at least 80% of cycle 1 were evaluable for DLT analysis. MTD was defined as the highest dose at which no more than 33% of patients developed a DLT. DLTs were defined as any clinically grade 3 or 4 non-hematologic toxicity as defined in the National Cancer Institute Common Terminology Criteria for Adverse Events version 4 (NCI CTCAE v4.0), expected and believed to be related to the study medications (except nausea and vomiting, electrolyte imbalances responsive to appropriate regimens or alopecia), any grade 4 hematologic toxicity lasting at least 3 weeks or longer (as defined by the NCI-CTCAE v4.0) or associated with bleeding and/or sepsis, any grade 4 nausea or vomiting lasting more than 5 days despite maximum anti-nausea regimens, any other grade 3 non-hematologic toxicity including symptoms/signs of vascular leak or cytokine release syndrome, and any severe life threatening complication or abnormality not defined in the NCI-CTCAE v4.0 that is attributable to the therapy observed during the first cycle (28 days) of therapy. If an individual experienced a new clinically significant toxicity grade 3 or greater, treatment was held until recovery to baseline levels or grade 1 or less and the drug to which the toxicity was attributed per physician was reduced by up to 50%. If it

was unclear which drug was responsible for the toxicity then both drugs were reduced by up to 50%.

Scans were performed prior to enrolling patient on treatment and every 2 cycles thereafter. Response to therapy was assessed according to the immune-related response criteria (irRC). (7) The response according to irRC is derived from time-point response assessments based on tumor burden and is divided into 4 categories, immune-related complete response (irCR), immune-related partial response (irPR), immune-related stable disease (irSD), and immune-related progressive disease (irPD). Of the responses irCR constitutes disappearance of all lesions without appearance of any new lesions whereas irPR means tumor burden has decrease by more than or equal to 50% relative to baseline and irPD means tumor burden has increased by more than or equal to 25% relative to nadir. Any response not meeting criteria for irCR or irPR in the absence of irPD is considered irSD.

Comprehensive genomic profiling was performed on DNA extracted from archival FFPE tumor samples from patients with available tissue using the Clinical Laboratory Improvement Amendments (CLIA)-certified, College of American Pathologists (CAP)-accredited, New York State (NYS)-approved Foundation One™ (DNA-seq) or the FoundationOne™ Heme (DNA/RNA-seq) assay. It had a mean coverage depth of 663x for DNA (up to 405 cancer-related genes) and ~3M on-target unique pairs for RNA (265 genes included). All classes of alterations (e.g. base substitution, short insertion or deletion [indel], focal gene amplification, homozygous deletion and selected rearrangements) were detected. At least 50ng of DNA per specimen was isolated and sequenced to high, uniform coverage (average median depth of 734X with 99% of bases covered >100X), as described previously. (8) Genomic alterations were determined for each patient sample. To maximize mutation detection sensitivity in heterogeneous specimens, we validated the test to detect base substitutions at a 5% mutant allele frequency (MAF) with 99% sensitivity and indels at a 10% MAF with 98% sensitivity, with a false discovery rate of <1% (8). Total mutational burden was defined as the number of somatic coding base substitutions and indel alterations minus known driver alterations per megabase (Mb) of genome examined adjusted for the tumor content. A TMB of ≥20 mutations/Mb was considered high; 6–19 mutations/Mb intermediate; and ≤5 mutations/Mb low.

Results

Patient characteristics

From May 2013 to May 2016, a total of 71 patients were screened. Of those, 36 met eligibility criteria, were financially cleared by insurance and received at least one dose of treatment (Figure 1). The 36 patients' clinical characteristics are shown in Table 2. Most patients treated were female (n=24, 67%), white (n=22, 61%), median age of 56 years (range, 19 to 75). The most frequently treated tumor types were Hodgkins lymphoma (n=7, 19%), melanoma (n=5, 14%), and leiomyosarcoma (n=4, 11%). The median number of prior therapies was 3 (range, 0 to 9). Total of 3 (8%) patients received prior ipilimumab and 1 (3%) prior lenalidomide (Table 2).

Toxicity

All 36 patients were evaluable for toxicity and 28 (78%) were evaluable for DLTs (patients had to complete 80% of planned dosing in cycle 1 or had a DLT). The MTD has not been reached and dose level 5 of intravenous ipilimumab 3mg/kg on day 1 and oral lenalidomide 25 mg on days 1 through 21 of a 28 day cycle was determined to be the RP2D. Further dose escalation was not pursued because lenalidomide was given in the FDA-approved dose for monotherapy and ipilimumab was also given in the FDA-approved dose except for being given every 4 weeks instead of 3 weeks. DLTs included grade 3 erythematous rash (3 patients) and grade 3 pancreatitis (1 patient, Table 1). Overall treatment related grade 3 or 4 toxicities included grade 3 rash (4 patients), grade 3 hypopituitarism (1 patient), grade 4 hypopituitarism (1 patient), grade 3 pancreatitis (1 patient), grade 3 pneumonitis (1 patient), grade 3 deep vein thrombosis (1 patient), grade 3 pulmonary embolism (1 patient), grade 3 anemia (5 patients), grade 3 thrombocytopenia (1 patient) and grade 3 transaminitis (1 patient, Table 3). In addition we observed the following treatment related significant grade 2 toxicities: rash (2 patients), hypopituitarism (1 patient), pneumonitis (1 patient), and deep vein thrombosis (3 patients, Table 3). Although, small numbers precluded formal statistical analysis the incidence of deep vein thrombosis/pulmonary embolism was between 7-20% (overall incidence 3/36, 8%) in patients on prophylactic low molecular heparin (1/5, 20%), prophylactic anti-aggregation therapy (2/16, 13%) and in patients on no prophylaxis (1/15, 7%).

Nine patients (25%) had dose interruption due to treatment-related adverse events (rash, n=5) and 5 patients (14%) were dose reduced (lenalidomide) for treatment related adverse events (rash, n=4). Of interest of 7 patients with Hodgkin lymphoma, 4 had a history of allogeneic transplant without clinically relevant symptoms of graft versus host disease (GVHD). None of these 4 patients experienced any autoimmune side effects or reactivation of GVHD. In addition, a patient with anaplastic thyroid cancer and HIV infection on highly active retroviral therapy did not have any significant adverse events.

Efficacy—Of 36 patients, 33 (92%) had at least one restaging imaging (Figure 2). Four patients did not have restaging scans because of DLT leading to treatment discontinuation (n=1), clinical progression (n=2) or death (n=1). The best response per irRC was 1 (3%) PR in a patient with refractory Hodgkin lymphoma (prior therapies included ABVD, ICE with panobinostat, brentuximab and autologous stem cell transplant), which has lasted for 7.2+ months. In addition, 7 patients experienced tumor shrinkage less than a PR: Hodgkin lymphoma –44%, melanoma –33%, Hodgkin lymphoma –27%, teratoma –15%, thyroid carcinoma –14%, thyroid carcinoma –5%, and Hodgkin lymphoma, –2% (Figure 2). Total of 16 (44%) patients had SD, which lasted for at least 4 months in 6 (17%) of them (Hodgkin lymphoma, 4.6 months; teratoma, 28.5+ months; Hodgkin lymphoma, 5.5 months; melanoma, 4.0 months; ovarian cancer, 5.8 months and leiomyosarcoma, 5 months, Figure 2). At the time of analysis, 5 patients continued on therapy and 31 patients were discontinued because of disease progression (n=29) or toxicity (n=2).

Comprehensive genomic profiling—Among the 36 patients treated on protocol, 17 patients with diverse cancers (leiomyosarcoma, n=4; renal cancer, n=3; thyroid cancer, n=2;

other cancers, n=6) available archival tissue had comprehensive genomic profiling to detect selected somatic molecular alterations and total mutation burden (TMB, mutations/Mb) using targeted next-generation sequencing Foundation One panel (Foundation Medicine, Cambridge, MA) and results along with treatment outcomes are depicted in Table 4. A total of 13 patients had low TMB (< 5 mutations/Mb), 2 patients (including one with a PR) had intermediate TMB (6-19 mutations/Mb), 1 high TMB (> 20 mutations/Mb) and 1 patient had no result (Table 4). Small numbers precluded analysis of association between TMB and treatment outcomes.

Discussion

Our study demonstrated that the combination of 3mg/kg of ipilimumab and 25mg of lenalidomide was well tolerated in patients with advanced metastatic malignancies. The DLTs encountered include grade 3 skin rash (n=3) and grade 3 pancreatitis (n=1). Skin rash was the most frequent grade 3 treatment related toxicity (11%). The rash presented as maculopapular in nature and generally appeared the second week of treatment on the trunk and extremities. In comparison, a phase 3 study in which melanoma patients were treated with single agent ipilimumab and a combination of ipilimumab with gp100 demonstrated the incidence of grade 3 skin rash to be 0.8% and 1.3% respectively.(1) The notably higher percentage can be attributed to rash being a feature of adding lenalidomide, which as a monotherapy is associated with grade 3 or 4 rash in up to 10% of patients.(9) Pancreatitis was seen in a single subject (3%) and presented within 2 days of initial dose of ipilimumab. This was a rare occurrence as immune related pancreatitis is seen in less than 1.5% patient receiving anti-CTLA-4 antibody treatment.(10) This patient was taken off treatment within 10 days of first dose due to elevated amylase and lipase levels accompanied by fever.(11, 12) We observed 2 episodes of grade 3 or 4 hypopituitarism among 36 patients treated (6%), which is somewhat higher than incidence of 1.5% observed with single agent ipilimumab in the registration phase III study in melanoma.(1) It remains unclear whether this was pure coincidence or related to the study combination or tumor types enrolled. Of interest, we did not observe any propensity to immune mediated side effects or reactivation of GVHD in patients with a history of allogeneic stem cell transplant, which was consistent with anecdotal data published in the literature.(13) Finally, only two patients were taken off therapy because of toxicity while remaining 29 patients discontinued the study due to disease progression.

Using bi-dimensional irRC we observed one PR (79%) in a patient with refractory Hodgkin lymphoma, which continues to be maintained for 7.2+ months. Tumor shrinkage less than PR was observed in additional 7 patients of whom 3 had refractory Hodgkin lymphoma. This is not unexpected since immunotherapy with PD1 antibodies demonstrated activity in refractory Hodgkin lymphoma.(14, 15) In addition, there were 6 patients with SD for > 4 months (4 to 28.5+ months). Our findings are consistent with published data suggesting that objective responses are infrequent; however, some patients can achieve durable disease control.(1, 16, 17)

Our study has several limitations. First, we experienced unusually high number of screen failures (n=35), most of them being related to problems with insurance clearance or consent

withdrawal during the screening period. Second, our safety profile was better than anticipated and we finished all preplanned 5 dose levels without reaching an MTD; however, since we did not perform pharmacokinetic analysis it cannot be ruled out that ipilimumab and lenalidomide might negatively affect each other's exposure. Third, despite observing signals of activity in several patients heterogeneity of tumor types enrolled precludes any definitive conclusion and did not identify predictive factors for efficacy despite performing analysis of total mutation burden in subset of patients. Fourth, the study was designed in 2012 shortly before the first phase I study with anti-PD1 antibody nivolumab was published. (18) PD1 antibodies demonstrated improved efficacy and better safety profile than ipilimumab and therefore might be better candidates for clinical testing of rational combinations. (19, 20) Currently, the combination of ipilimumab and lenalidomide is being tested in post stem cell transplant setting in patients with advanced leukemia and lymphoma (NCT01919619).

Acknowledgments

This study and all authors were supported by the National Center for Advancing Translational Sciences (grant no. UL1 TR000371); by the National Institutes of Health through MD Anderson's Cancer Center Support Grant (P30 CA016672).

Conflict of Interest: Vivek Subbiah received research funding from Novartis, Bayer, Loxo, Nanocarrier, Abbvie, Pharmamar, Blueprint Medicines, and Genentech. David S. Hong received research funding from Adaptimmune, Abbvie, Amgen, Astra-Zeneca, Bayer, BMS, Daiichi-Sanko, Eisai, Genentech, Ignyta, Infinity, Kite, Kyowa, Lilly, Loxo, Mirati, Merck, Medimmune, Molecular Template, Novartis, Pfizer, Takeda, MiRNA; is on advisory board for Baxter, Bayer, Guidepoint Global, Janssen and has ownership interests in Molecular Match and OncoResponse. Filip Janku received research funding from Novartis, BioMed Valley Discoveries and Foundation Medicine and was on ad hoc advisory board for Foundation Medicine.

Financial information: This study was supported by the National Center for Advancing Translational Sciences (grant no. UL1 TR000371, Principal Investigator D. D. McPherson); by the National Institutes of Health through MD Anderson's Cancer Center Support Grant (P30 CA016672, Principal Investigator E. Dimitrovsky).

References

1. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. *N Engl J Med*. 2011; 363:711–23.
2. Zeldis JB, Knight R, Hussein M, Chopra R, Muller G. A review of the history, properties, and use of the immunomodulatory compound lenalidomide. *Ann N Y Acad Sci*. 2011; 1222:76–82. [PubMed: 21434945]
3. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. *Nat Med*. 2002; 8:793–800. [PubMed: 12091876]
4. Zhu D, Corral LG, Fleming YW, Stein B. Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. *Cancer Immunol Immunother*. 2008; 57:1849–59. [PubMed: 18392823]
5. Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. *Blood*. 2001; 98:210–6. [PubMed: 11418482]
6. Gorgun G, Samur MK, Cowens KB, Paula S, Bianchi G, Anderson JE, et al. Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma. *Clin Cancer Res*. 2015; 21:4607–18. [PubMed: 25979485]
7. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbe C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. *Clin Cancer Res*. 2009; 15:7412–20. [PubMed: 19934295]

8. He J, Abdel-Wahab O, Nahas MK, Wang K, Rampal RK, Intlekofer AM, et al. Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting. *Blood*. 2016; 127:3004–14. [PubMed: 26966091]
9. Nardone B, Wu S, Garden BC, West DP, Reich LM, Lacouture ME. Risk of rash associated with lenalidomide in cancer patients: a systematic review of the literature and meta-analysis. *Clin Lymphoma Myeloma Leuk*. 2013; 13:424–9. [PubMed: 23769670]
10. Weber J. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. *Oncologist*. 2007; 12:864–72. [PubMed: 17673617]
11. Di Giacomo AM, Danielli R, Guidoboni M, Calabro L, Carlucci D, Miracco C, et al. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases. *Cancer Immunol Immunother*. 2009; 58:1297–306. [PubMed: 19139884]
12. Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. *J Clin Oncol*. 2005; 23:6043–53. [PubMed: 16087944]
13. Bashey A, Medina B, Corringham S, Pasek M, Carrier E, Vrooman L, et al. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. *Blood*. 2009; 113:1581–8. [PubMed: 18974373]
14. Armand P, Shipp MA, Ribrag V, Michot JM, Zinzani PL, Kuruvilla J, et al. Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure. *J Clin Oncol*. 2016
15. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. *N Engl J Med*. 2015; 372:311–9. [PubMed: 25482239]
16. O'Mahony D, Morris JC, Quinn C, Gao W, Wilson WH, Gause B, et al. A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. *Clin Cancer Res*. 2007; 13:958–64. [PubMed: 17289891]
17. Amato RJ, Hernandez-McClain J, Saxena S, Khan M. Lenalidomide therapy for metastatic renal cell carcinoma. *Am J Clin Oncol*. 2008; 31:244–9. [PubMed: 18525302]
18. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. *N Engl J Med*. 2012; 366:2443–54. [PubMed: 22658127]
19. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. *N Engl J Med*. 2015; 372:320–30. [PubMed: 25399552]
20. Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. *N Engl J Med*. 2015; 373:123–35. [PubMed: 26028407]

Figure 1.
Enrollment of patients with advanced cancer to the dose escalation study with ipilimumab and lenalidomide.

Figure 2.

Waterfall plots shows the best change in size of target lesions assessed using the immune-related response criteria (irRC). Of 36 patients (33 had at least one restaging scan and 31 had measurable disease), there was one partial response (PR) and 7 regressions less than PR. In addition, total of 16 patients had stable disease lasting for 4 months or longer. Time to treatment failure is depicted below or above bars indicating the change in target lesion (+ indicates ongoing therapy). Patients without measurable disease or restaging scan are depicted on the right of the axis

Table 1

Dose escalation and dose limiting toxicities.

Dose level	Ipilimumab IV q 28 days × 4	Lenalidomide PO daily × 21 q 28 days until disease progression	Number of patients (patients evaluable for DLT)	DLT event
1	1.5 mg/kg	10mg	4 (3)	
2	1.5 mg/kg	15mg	11 (8)	G3 rash, G3 pancreatitis
3	3 mg/kg	15mg	8 (6)	G3 rash
4	3 mg/kg	20mg	5 (4)	
5	3 mg/kg	25mg	8 (7)	G3 rash

Table 2

Patients characteristics (N=36)

Patient Characteristics	Number
Median age, years (range)	56 (19-75)
Gender, N (%)	
Male	12 (33)
Female	24 (67)
Ethnicity, N (%)	
White	22 (61)
African-American	5 (14)
Hispanic	4 (11)
Other	5 (14)
ECOG performance status, N (%)	
0	6 (17)
1	27 (75)
2	3 (8)
Prior therapies	
Median prior therapies, N (range)	3 (0-9)
<5 therapies, N (%)	25 (69)
>= 5 therapies, N (%)	11 (31)
Prior ipilimumab, N (%)	3 (8)
Prior lenalidomide, N (%)	1 (3)
Prior allogenic stem cell transplant (%)	4 (11)
Diagnosis, N (%)	
Melanoma	5 (14)
Thyroid cancer	3 (8)
Adrenocortical cancer	2 (6)
Adenoid cystic cancer	2 (6)
Leiomyosarcoma	4 (11)
Hodgkin Lymphoma	7 (19)
Renal cancer	3 (8)
Other (cervical, colorectal, peritoneal, ovarian, triple negative breast, squamous cell head and neck, chondrosarcoma, osteosarcoma, carcinosarcoma and teratoma)	10 (28)

Table 3

Treatment related toxicities (mild grade 1 toxicities are not depicted).

Toxicity	Grade 2	Grade 3	Grade 4
Anemia	1 (3)	5 (14)	0
Thrombocytopenia	0	1 (3)	0
Rash ¹	2 (6)	4 (11)	0
Hypopituitarism ²	1 (3)	1 (3)	1 (3)
Pancreatitis	0	1 (3)	0
Pneumonitis	1 (3)	1 (3)	0
Deep vein thrombosis	3 (8)	1 (3)	0
Pulmonary embolism	0	1 (3)	0
Transaminitis	0	1 (3)	0

¹Grade 1 rash was observed in 8 patients,

²Grade 1 hypopituitarism in 1 patient

Table 4

Comprehensive genomic profiling of archival tumor tissue for common genomic alterations and total mutation burden and outcomes

ID	Cancer type	Molecular alterations	Total mutation burden in mutation/Mb	irRC response %	Time to treatment failure in months
5	Anaplastic thyroid carcinoma	NF1 11845fs*13, VHL E52*, CDKN2A/B loss	5	25	0.9
6	Hurtle cell thyroid carcinoma	DAXX C629fs*16, RB1 D68fs*37, TP53 R175H	3	-14	2.1
7	Immature teratoma	No abnormality	3	-15	28.5+
9	SCCHN	No abnormality	Not done	25	1.6
10	Leiomyosarcoma	PTEN loss, TP53 217V_218VinsVPYERPE	1	86	1.3
11	Renal cell carcinoma	BAP1 splice site 375+2T>C, PBRM1 F786fs*5	3	32	3.7
12	Chondrosarcoma	NOTCH2 C1400*, SETD2 K1486fs*3	1	22	2.5
13	Leiomyosarcoma	EGFR CNV, AURKB CNV eq, C17orf39 CNV eq, RB1 loss, TP53 loss	7	25	1.5
16	Uterine carcinosarcoma	TP53 K132R	5	25	1.8
19	Renal medullary carcinoma	SMARCB1 splice site 603_628+26del52, SETD2 G1690fs*15, SPTA1 splice site 2996+2T>A	5	76	3.4
20	Melanoma [/]	NF1 loss, GNAQ Q209P, NRAS Q61H sub, ATR splice site 4267_4267-1GG>AA, CKN2A/B, RB1 E50*, ARID2 R274*, ARID2 F1237fs*6, BCOR R810*	81	13	2.1
22	Renal cell carcinoma	MYC CNV, SF3B1 D781G	1	68	1.9
26	Adrenocortical carcinoma	No abnormality	5	31	1.2
27	Adrenocortical carcinoma	ERBB3 CNV EQ, FGFR4 CNV EQ, MAP2K2 CNV EQ, CCNE1 CNV	4	22	3.0
28	Leiomyosarcoma	TP53 C135Y, KDM6A Q679fs*12, RB1 loss, ATRX E492*	5	99	1.8
30	Hodgkin lymphoma	IGH-SOCS1 rearrangement	10	-79	7.2+
32	Leiomyosarcoma	RB1 L337fs*12, TP53 G266R	4	24	5.0

[/] patient received prior ipilimumab